Customize your JAMA Network experience by selecting one or more topics from the list below.
To the Editor We question the conclusion of Wu et al1 about the benefit of corticosteroid use in the treatment of coronavirus disease 2019 (COVID-19). The World Health Organization and the US Centers for Disease Control and Prevention have issued clinical guidance against the use of corticosteroids in the treatment of COVID-19 unless another indication is present, such as a chronic obstructive pulmonary disease exacerbation, or as adjunct treatment of septic shock. This guidance was made on the basis of systematic reviews of observational studies of corticosteroids that demonstrated an association with increased mortality and secondary infections in influenza2 and no benefit with possible harms in severe acute respiratory syndrome.3 A retrospective cohort study of Middle East respiratory syndrome showed that corticosteroids were associated with no difference in mortality and prolonged respiratory viral shedding.4
It is unclear that the proportional hazards analysis in the study modeled methylprednisolone administration as a time-dependent covariate, which is necessary to mitigate what has been termed survivor treatment selection bias.5 Stated simply, patients who died rapidly may have been less likely to receive methylprednisolone, leading to an observed difference in mortality that was incorrectly associated with this intervention. Mortality was 23 of 50 (46%) among those with acute respiratory distress syndrome who received methylprednisolone vs 21 of 34 (62%) among those who did not. Even if there were no bias present and methylprednisolone provided some short-term survival benefit, the end point difference of 16% less mortality in those who received corticosteroids is not significant (95% CI, −40% to 8%; P = .23). From the Kaplan-Meier curves, the ultimate mortality rate was roughly similar in both groups—around 60%.
Corresponding Author: Grant B. Ellsworth, MD, MS, Weill Cornell Medicine, 53 W 23rd St, 6th Floor, New York, NY 10010 (email@example.com).
Published Online: August 3, 2020. doi:10.1001/jamainternmed.2020.2444
Conflict of Interest Disclosures: Dr Ellsworth reported grants from the AIDS Malignancy Consortium and the National Institute of Allergy and Infectious Diseases, as well as nonfinancial support from Weill Cornell Clinical & Translational Science Center. Dr Glesby reported grants from Gilead Sciences and royalties from UpToDate and Springer. No other disclosures were reported.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Ellsworth GB, Glesby MJ, Gulick RM. The Uncertain Role of Corticosteroids in the Treatment of COVID-19. JAMA Intern Med. 2021;181(1):140. doi:10.1001/jamainternmed.2020.2444
Coronavirus Resource Center
Create a personal account or sign in to: